H. Talia Zhang, MD, ScD, is Senior Vice President, Global Safety, Pharmacovigilance, and Benefit-Risk at Kyverna Therapeutics. Talia is a physician-scientist and biopharmaceutical executive with more than 20 years of experience leading safety, clinical development, and epidemiology programs across complex biologics and immune-modulating therapies and has contributed to more than 10 product approvals.

Prior to joining Kyverna, Talia was Principal and Co-founder of CK Imaging, a clinical research organization focused on clinical development and safety. Previously, she served as Senior Vice President of Clinical Development, Pharmacovigilance, and Biometrics at Krystal Biotech, where she worked on the development of gene therapy programs. She has also served as Chief Medical Officer and Head of Patient Safety and Epidemiology at Emergent BioSolutions, as Chief Safety Officer at FibroGen, and as VP and Global Head of Oncology Benefit-Risk Management and Pharmacovigilance at Bayer. Earlier in her career, she held roles of increasing responsibility at Genzyme, Amgen, BMS, and AbbVie.

Prior to joining industry, Talia served as a Safety Officer at U.S. Food and Drug Administration. She has contributed to international scientific and regulatory initiatives and has authored multiple scientific publications and presented at leading medical forums. Talia holds a Doctor of Medicine and completed her training in both China and at the University of California, San Francisco School of Medicine. She also completed studies in Neurobiology and Medical Science at the University of California, Berkeley, and holds a Doctor of Science in Cancer Epidemiology with a minor in Biostatistics from Harvard University.